Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trialEndry H. T. Lim, Rutger Koning, Matthijs C. Brouwer et al.|Respiratory Research|2022Cited by 18